logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Apnimed acquires global rights to sulthiame

Apr 25, 2025•8 months ago

Acquiring Company

Apnimed

Acquired Company

Desitin Arzneimittel GmbH

CambridgeHamburgManufacturingPharmaceuticalBiotechnologyHealth CareManufacturing

Description

Apnimed, Inc. has acquired the exclusive global rights to develop and commercialize sulthiame, a differentiated carbonic anhydrase inhibitor, from Desitin Arzneimittel GmbH. This acquisition will enhance Apnimed's portfolio in treating obstructive sleep apnea (OSA) through its joint venture with Shionogi. Sulthiame has completed successful Phase 2 trials and is approved for use in non-sleep-related diseases outside the US.

Company Information

Company

Apnimed

Location

39 John F. Kennedy Street, 4th Fl

Cambridge, Massachusetts, United States

About

Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed